| 前收市價 | 51.18 |
| 開市 | 50.90 |
| 買盤 | 51.64 x 400 |
| 賣出價 | 51.70 x 400 |
| 今日波幅 | 50.87 - 51.85 |
| 52 週波幅 | 50.27 - 75.74 |
| 成交量 | |
| 平均成交量 | 1,765,296 |
| 市值 | 11.604B |
| Beta 值 (5 年，每月) | 0.67 |
| 市盈率 (最近 12 個月) | 19.50 |
| 每股盈利 (最近 12 個月) | 2.65 |
| 業績公佈日 | 2024年4月30日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 74.29 |
ZacksThe Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
ZacksBiotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement.
ZacksAllogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?
Allogene Therapeutics (ALLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
